Topic

Blenrep (belantamab mafodotin)

A collection of 9 issues

Getting Blenrep (Belantamab Mafodotin) Covered by Aetna CVS Health in Georgia: Appeals Guide and External Review Process

Answer Box: Blenrep Coverage Path for Georgia Residents Blenrep (belantamab mafodotin) is currently off-market in the US (withdrawn 2022, resubmission under FDA review). For Georgia residents with Aetna CVS Health, access is limited to clinical trials or expanded access programs. If denied coverage for trial participation or compassionate use: 1.

Renewing Blenrep (Belantamab Mafodotin) Approval with UnitedHealthcare in Pennsylvania: Timeline, Documents & Appeal Process

Quick Answer: Blenrep Renewal with UnitedHealthcare in Pennsylvania Current Status: Blenrep (belantamab mafodotin) was withdrawn from the U.S. market in 2022 and is only available through clinical trials or expanded access programs. UnitedHealthcare typically denies coverage outside these settings. For trial-related bridge therapy or expanded access, submit prior authorization

How to Get Blenrep (Belantamab Mafodotin) Covered by Cigna in Pennsylvania: Complete Appeals Guide

Answer Box: Getting Blenrep Covered by Cigna in Pennsylvania Blenrep (belantamab mafodotin) is currently withdrawn from the U.S. market as of 2022, with FDA resubmission under review (PDUFA date October 2025). Access is limited to clinical trials or expanded access programs. If you're seeking coverage, you'

Do You Qualify for Blenrep (Belantamab Mafodotin) Coverage by Humana in Ohio? Decision Tree & Next Steps

Answer Box: Quick Eligibility & Action Plan Blenrep (belantamab mafodotin) was reapproved by the FDA on October 23, 2025 for relapsed/refractory multiple myeloma after ≥2 prior therapies. For Humana coverage in Ohio: (1) Confirm your diagnosis meets FDA criteria, (2) Have your oncologist submit prior authorization with clinical documentation

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in Illinois: Complete Timeline & Appeals Guide

Answer Box: Getting Blenrep Covered by Aetna in Illinois Blenrep (belantamab mafodotin) received FDA approval on October 23, 2025 for relapsed/refractory multiple myeloma. For Aetna coverage in Illinois: 1. Check eligibility: Must have relapsed/refractory multiple myeloma after ≥2 prior therapies including a proteasome inhibitor and immunomodulatory agent 2.

How to Get Blenrep (Belantamab Mafodotin) Covered by Blue Cross Blue Shield of Illinois: Coding, Appeals, and Current Access Options

Answer Box: Blenrep Coverage with Blue Cross Blue Shield of Illinois Current Status: Blenrep (belantamab mafodotin) is not commercially available in the U.S. as of 2025—GSK withdrew it in 2022 pending FDA resubmission (PDUFA date October 2025). Blue Cross Blue Shield of Illinois (BCBSIL) requires prior authorization for

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in New York: Complete Guide to Appeals and Access

Quick Answer: Getting Blenrep Covered by Aetna in New York Important Update: Blenrep (belantamab mafodotin) was voluntarily withdrawn from the U.S. market in 2022 and is currently under FDA review with a decision expected October 23, 2025. Standard commercial coverage through Aetna is not available at this time. Current

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in California: Decision Tree, Appeals, and Access Options

Answer Box: Your Path to Blenrep Coverage in California Blenrep (belantamab mafodotin) is currently unavailable for commercial coverage through Aetna CVS Health because GSK withdrew it from the U.S. market in November 2022. The FDA is reviewing resubmission with a PDUFA date of October 23, 2025. Your fastest path

Getting Blenrep (Belantamab Mafodotin) Covered by Humana in Virginia: Complete Guide to Access, Appeals, and Clinical Trial Options

Answer Box: Quick Path to Blenrep Access in Virginia Blenrep (belantamab mafodotin) is currently unavailable for commercial coverage in the U.S. as GSK resubmits for FDA approval (decision expected October 23, 2025). Virginia patients with Humana can access Blenrep only through: 1. Clinical trials - Contact your oncologist about